Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT03014141
Other study ID # 2015-12-10-OAT
Secondary ID
Status Withdrawn
Phase N/A
First received
Last updated
Start date June 2018
Est. completion date March 2019

Study information

Verified date August 2018
Source DSM Nutritional Products, Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The consumption of oat bran fiber also has a significant bulking effect in humans. However, besides fecal bulk, dietary fiber can promote gut health in other ways. Therefore, the purpose of this study is to investigate the effects of oat bran (rich in oat beta-glucan) supplementation on bowel function and appetite.


Description:

The study is a randomized, double-blind, placebo-controlled crossover study it involves a total of 8 visits with a 14 day run-in period for total study duration of 84 days. A washout period of 2 weeks will occur in between the 2, 28 day treatment periods. The effects of an oat bran beverage for breakfast on bowel function will be tested after 2 week and 4 weeks of intake.


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date March 2019
Est. primary completion date December 2018
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 60 Years
Eligibility Inclusion Criteria:

- Healthy male or female between the ages of 18-60 years

- Subject has a body mass index of =18.5 and =30 kg/m2 at screening visit.

- Subject is willing to stick to their normal habitual diet excluding the consumption of any unusual high energy-rich or fat-rich meals or prolonged fasting, etc. through the study period.

- Subject is willing to maintain their habitual physical activity patterns throughout the study period.

- Subject has been weight stable within the last 6 months.

- Subject has no health conditions that would prevent him or her from fulfilling the study requirements as judged by the investigator on the basis of medical history and routine laboratory test results.

- Low fiber consumer (=14 g per day)

- Subject is willing to follow study procedures and dietary restrictions (ex: stick to habitual diet, refrain from consuming alcohol 24 hours prior to test days).

Exclusion Criteria:

- History of a gastrointestinal disorder

- Lactose intolerant

- High fiber consumer (=15 g per day)

- Use of pre-and probiotics in the past 90 days

- High protein consumer (i.e. vegetarians or those who follow diets high in protein such as paleo)

- History of psychological illness or conditions that may interfere with subjects ability to understand study directions

- Use of antibiotics or signs of active systemic infection in the last 6 months.

- Subjects who are on hypo/hypercaloric diet aiming for weight loss or weight gain

- History or presence of cancer in the prior 2 years (except for non-melanoma skin cancer).

- Currently pregnant, lactating or planning to be pregnant during the study period

- Regular use of dietary supplements (ex: fish oil, riboflavin, etc.), 90 days prior to study inclusion

- Exposure to any non-registered drug product within the last 30 days prior to screening visit

- History of or strong potential for alcohol or substance abuse (within 12 months of screening visit). Alcohol abuse is defined as >60g (men)/40g (women) pure alcohol per day (1.5 L/ 1 l beer resp. 0.75l/0.5l wine).

- Allergy or sensitivity to oat bran or any meals or snacks provided

- Current smoker or use of tobacco products in the past 90 days

- Concurrent or recent participation (30 days) in a dietary intervention trial

- Anything in the judgment of the investigator would interfere with the subject's ability to comply with the study (protocol), which might confound the interpretation of the study results, or put the subject at undue risk.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Oat bran (Oatwell 28)
11 g oat bran containing 3.1 gram oat beta-glucan
Maltodextrin
11 g of Maltodextrin

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
DSM Nutritional Products, Inc.

References & Publications (3)

Chen HL, Haack VS, Janecky CW, Vollendorf NW, Marlett JA. Mechanisms by which wheat bran and oat bran increase stool weight in humans. Am J Clin Nutr. 1998 Sep;68(3):711-9. — View Citation

Grabitske HA, Slavin JL. Low-digestible carbohydrates in practice. J Am Diet Assoc. 2008 Oct;108(10):1677-81. doi: 10.1016/j.jada.2008.07.010. Review. — View Citation

Stewart ML, Nikhanj SD, Timm DA, Thomas W, Slavin JL. Evaluation of the effect of four fibers on laxation, gastrointestinal tolerance and serum markers in healthy humans. Ann Nutr Metab. 2010;56(2):91-8. doi: 10.1159/000275962. Epub 2010 Jan 19. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Whole gut transit time Whole gut transit time is the time required for the passage of 80% of radio-opaque markers (ROM) which are detected by x-ray in the fecal samples collected over the next 5 days after swallowing the ROM. 4 weeks
Secondary Whole gut transit time Whole gut transit time is the time required for the passage of 80% of radio-opaque markers (ROM) which are detected by x-ray in the fecal samples collected over the next 5 days after swallowing the ROM. 2 weeks
Secondary Stool frequency using a bowel movement diary 2 weeks and 4 weeks
Secondary Fecal output Fecal out is the weight of the fecal samples collected over the 5 days preceding the 2 week and 4 week time point 2 weeks and 4 weeks
Secondary Percent fecal moisture Fecal moisture is determined by freeze drying fecal samples and calculating the percent moisture in the fecal sample 2 weeks and 4 weeks
Secondary Bristol Stool Score using Bristol Stool Chart 2 weeks and 4 weeks
Secondary Fecal pH 2 weeks and 4 weeks
Secondary Subjective measures of bowel comfort Gastrointestinal Quality of life questionnaires (GIQLI) 2 weeks and 4 weeks
Secondary Gut microbiota Using 16S ribosomal RNA sequencing techniques 2 weeks and 4 weeks
Secondary Fecal short chain fatty acids Using gas chromatography 2 weeks and 4 weeks
Secondary Fecal total bile acids 2 weeks and 4 weeks
Secondary Fecal enzymes fecal beta-glucoronidase 2 weeks and 4 weeks
Secondary Fecal ammonia 2 weeks and 4 weeks
Secondary Intestinal gas production using breath hydrogen production 2 weeks and 4 weeks
Secondary Appetite Appetite will be measured via visual analogue score (VAS) 2 weeks and 4 weeks
Secondary Ad libitum energy intake Ad libitum energy intake is measured by serving the subject an excess of food 2 weeks and 4 weeks
See also
  Status Clinical Trial Phase
Completed NCT03269617 - PHAGE Study: Bacteriophages as Novel Prebiotics N/A
Terminated NCT02974686 - Conversion From MPA to Zortress (Everolimus) for GI Toxicity Post-renal Transplantation Phase 4
Active, not recruiting NCT05363553 - Transition to Infant Formula Feeding on Gastrointestinal Regurgitation (TIGER) Study N/A
Completed NCT03102411 - Impact of Diet on Functional Gastrointestinal Symptoms
Completed NCT04530929 - Analysis of the Impact of Used Probiotic Strains and Diet on Body Composition, Cardiopulmonary Efficiency and the Incidence of Gastrointestinal Disorders in Runners N/A
Completed NCT05915767 - Therapeutic Effect of Olive Leaf Tea on SIBO N/A
Recruiting NCT03011151 - Protease Activated Receptor-2 and Gastrointestinal Dysfunction in Critical Illness